Ocular Therapeutix Inc

NASDAQ:OCUL   4:00:00 PM EDT
2.97
+0.10 (+3.48%)
6:36:20 PM EDT: $3.00 +0.03 (+1.01%)
Products, Regulatory, Earnings Announcements

Ocular Therapeutix Announces Interim 7-Month Data From U.S. Early Stage Clinical Trial Of OTX-TKI For Treatment Of Wet AMD

Published: 09/27/2022 10:13 GMT
Ocular Therapeutix Inc (OCUL) - Ocular Therapeutix™ Announces Interim 7-month Data From U.S. Phase 1 Clinical Trial of Otx-tki for the Treatment of Wet Amd.
Ocular Therapeutix Inc - Otx-tki Was Well Tolerated and Demonstrated a Favorable Safety Profile With No Drug-related Ocular Or Systemic Saes.
Ocular Therapeutix Inc - Plans to Initiate a U.S.-based Phase 1 Clinical Trial to Evaluate Otx-tki for Treatment of Diabetic Retinopathy in Q1 of 2023.
Ocular Therapeutix Inc - Plans to Initiate a Phase 2 Wet Amd Clinical Trial in Q3 of 2023.
Revenue is expected to be $12.64 Million
Adjusted EPS is expected to be -$0.29

Next Quarter Revenue Guidance is expected to be $16.33 Million
Next Quarter EPS Guidance is expected to be -$0.25

More details on our Analysts Page.